One Year Duration of Immune Response Following a 3rd Booster Dose of mRNA Vaccine Against COVID‐19 in 292 Patients With Hematological Malignancies in University Hospital Ostrava, Czech Republic
ABSTRACT Aims To evaluate antibody response to mRNA vaccine, identify subgroups with poor response and to determine long‐term antibody durability in hematological patients. Materials and Methods We have vaccinated 292 patients with all hematological malignancies with a third dose of mRNA COMIRNATY v...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.70503 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832593689729302528 |
|---|---|
| author | Ondrej Šušol Barbora Šušolová Ondřej Klempíř Milan Navrátil Jaromír Gumulec Zdeněk Kořístek Juraj Ďuraš Michal Kaščák Jana Mihályová Lukáš Stejskal Tomáš Jelínek Petra Richterová Lenka Szeligová Hana Plonková Jana Zuchnická Barbora Dluhošová Ivo Demel David Buffa Katarína Hradská Tereza Popková Ludmila Muroňová Martin Lachnit Klára Lančová Roman Hájek |
| author_facet | Ondrej Šušol Barbora Šušolová Ondřej Klempíř Milan Navrátil Jaromír Gumulec Zdeněk Kořístek Juraj Ďuraš Michal Kaščák Jana Mihályová Lukáš Stejskal Tomáš Jelínek Petra Richterová Lenka Szeligová Hana Plonková Jana Zuchnická Barbora Dluhošová Ivo Demel David Buffa Katarína Hradská Tereza Popková Ludmila Muroňová Martin Lachnit Klára Lančová Roman Hájek |
| author_sort | Ondrej Šušol |
| collection | DOAJ |
| description | ABSTRACT Aims To evaluate antibody response to mRNA vaccine, identify subgroups with poor response and to determine long‐term antibody durability in hematological patients. Materials and Methods We have vaccinated 292 patients with all hematological malignancies with a third dose of mRNA COMIRNATY vaccine with a 12‐month follow‐up period in our center in Ostrava, Czech Republic. Results Antibody response for the whole cohort exceeded 74% through the whole 12‐month follow‐up. Lowest seroconversion was observed in CLL cohort (20/41, 48.8%), patients who received anti‐CD20 therapy < 6 months before vaccination (8/30, 26.7%) and BTK inhibitors (3/6, 50.0%). On the contrary, patients with chronic myeloproliferative neoplasms and acute leukemia performed comparably with healthy population (33/33; 100% and 12/13; 92.3%, respectively). We have seen better results if the time interval between anti‐CD20 therapy and additional vaccine dose was longer than 6 months (5/8 patients achieved seroconversion on 4th booster dose after previous failure). Also, 36 patients received a 4th dose of vaccine as a booster with measurable increase in protective antibodies in 50% (18/36). Conclusions Additional doses show promise for a well‐timed revaccination even in poor responders. To our knowledge, no study comparable to our work in terms of follow‐up length, vaccine consistency or variety of hematological malignancies and/or treatment has been reported yet. Our findings shed more light on long‐term antibody response to mRNA vaccines against SARS‐CoV‐2 in patients with hematological cancer and bring important data for the evaluation of possible vaccine failure and scheduling of subsequent doses. |
| format | Article |
| id | doaj-art-860d1869852845298362b4a342e0ae4e |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-860d1869852845298362b4a342e0ae4e2025-01-20T10:51:32ZengWileyCancer Medicine2045-76342024-12-011324n/an/a10.1002/cam4.70503One Year Duration of Immune Response Following a 3rd Booster Dose of mRNA Vaccine Against COVID‐19 in 292 Patients With Hematological Malignancies in University Hospital Ostrava, Czech RepublicOndrej Šušol0Barbora Šušolová1Ondřej Klempíř2Milan Navrátil3Jaromír Gumulec4Zdeněk Kořístek5Juraj Ďuraš6Michal Kaščák7Jana Mihályová8Lukáš Stejskal9Tomáš Jelínek10Petra Richterová11Lenka Szeligová12Hana Plonková13Jana Zuchnická14Barbora Dluhošová15Ivo Demel16David Buffa17Katarína Hradská18Tereza Popková19Ludmila Muroňová20Martin Lachnit21Klára Lančová22Roman Hájek23Department of Haemato‐Oncology University Hospital Ostrava Ostrava Czech RepublicDepartment of Haemato‐Oncology University Hospital Ostrava Ostrava Czech RepublicDepartment of Biomedical Informatics, Faculty of Biomedical Engineering Czech Technical University in Prague Prague Czech RepublicDepartment of Haemato‐Oncology University Hospital Ostrava Ostrava Czech RepublicDepartment of Haemato‐Oncology University Hospital Ostrava Ostrava Czech RepublicDepartment of Haemato‐Oncology University Hospital Ostrava Ostrava Czech RepublicDepartment of Haemato‐Oncology University Hospital Ostrava Ostrava Czech RepublicDepartment of Haemato‐Oncology University Hospital Ostrava Ostrava Czech RepublicDepartment of Haemato‐Oncology University Hospital Ostrava Ostrava Czech RepublicDepartment of Haemato‐Oncology University Hospital Ostrava Ostrava Czech RepublicDepartment of Haemato‐Oncology University Hospital Ostrava Ostrava Czech RepublicDepartment of Haemato‐Oncology University Hospital Ostrava Ostrava Czech RepublicDepartment of Haemato‐Oncology University Hospital Ostrava Ostrava Czech RepublicDepartment of Haemato‐Oncology University Hospital Ostrava Ostrava Czech RepublicDepartment of Haemato‐Oncology University Hospital Ostrava Ostrava Czech RepublicDepartment of Haemato‐Oncology University Hospital Ostrava Ostrava Czech RepublicDepartment of Haemato‐Oncology University Hospital Ostrava Ostrava Czech RepublicDepartment of Haemato‐Oncology University Hospital Ostrava Ostrava Czech RepublicDepartment of Haemato‐Oncology University Hospital Ostrava Ostrava Czech RepublicDepartment of Haemato‐Oncology University Hospital Ostrava Ostrava Czech RepublicDepartment of Haemato‐Oncology University Hospital Ostrava Ostrava Czech RepublicDepartment of Haemato‐Oncology University Hospital Ostrava Ostrava Czech RepublicDepartment of Haemato‐Oncology University Hospital Ostrava Ostrava Czech RepublicDepartment of Haemato‐Oncology University Hospital Ostrava Ostrava Czech RepublicABSTRACT Aims To evaluate antibody response to mRNA vaccine, identify subgroups with poor response and to determine long‐term antibody durability in hematological patients. Materials and Methods We have vaccinated 292 patients with all hematological malignancies with a third dose of mRNA COMIRNATY vaccine with a 12‐month follow‐up period in our center in Ostrava, Czech Republic. Results Antibody response for the whole cohort exceeded 74% through the whole 12‐month follow‐up. Lowest seroconversion was observed in CLL cohort (20/41, 48.8%), patients who received anti‐CD20 therapy < 6 months before vaccination (8/30, 26.7%) and BTK inhibitors (3/6, 50.0%). On the contrary, patients with chronic myeloproliferative neoplasms and acute leukemia performed comparably with healthy population (33/33; 100% and 12/13; 92.3%, respectively). We have seen better results if the time interval between anti‐CD20 therapy and additional vaccine dose was longer than 6 months (5/8 patients achieved seroconversion on 4th booster dose after previous failure). Also, 36 patients received a 4th dose of vaccine as a booster with measurable increase in protective antibodies in 50% (18/36). Conclusions Additional doses show promise for a well‐timed revaccination even in poor responders. To our knowledge, no study comparable to our work in terms of follow‐up length, vaccine consistency or variety of hematological malignancies and/or treatment has been reported yet. Our findings shed more light on long‐term antibody response to mRNA vaccines against SARS‐CoV‐2 in patients with hematological cancer and bring important data for the evaluation of possible vaccine failure and scheduling of subsequent doses.https://doi.org/10.1002/cam4.70503CancerCOVID‐19LeukemiaLymphomaMyelomaVaccination |
| spellingShingle | Ondrej Šušol Barbora Šušolová Ondřej Klempíř Milan Navrátil Jaromír Gumulec Zdeněk Kořístek Juraj Ďuraš Michal Kaščák Jana Mihályová Lukáš Stejskal Tomáš Jelínek Petra Richterová Lenka Szeligová Hana Plonková Jana Zuchnická Barbora Dluhošová Ivo Demel David Buffa Katarína Hradská Tereza Popková Ludmila Muroňová Martin Lachnit Klára Lančová Roman Hájek One Year Duration of Immune Response Following a 3rd Booster Dose of mRNA Vaccine Against COVID‐19 in 292 Patients With Hematological Malignancies in University Hospital Ostrava, Czech Republic Cancer Medicine Cancer COVID‐19 Leukemia Lymphoma Myeloma Vaccination |
| title | One Year Duration of Immune Response Following a 3rd Booster Dose of mRNA Vaccine Against COVID‐19 in 292 Patients With Hematological Malignancies in University Hospital Ostrava, Czech Republic |
| title_full | One Year Duration of Immune Response Following a 3rd Booster Dose of mRNA Vaccine Against COVID‐19 in 292 Patients With Hematological Malignancies in University Hospital Ostrava, Czech Republic |
| title_fullStr | One Year Duration of Immune Response Following a 3rd Booster Dose of mRNA Vaccine Against COVID‐19 in 292 Patients With Hematological Malignancies in University Hospital Ostrava, Czech Republic |
| title_full_unstemmed | One Year Duration of Immune Response Following a 3rd Booster Dose of mRNA Vaccine Against COVID‐19 in 292 Patients With Hematological Malignancies in University Hospital Ostrava, Czech Republic |
| title_short | One Year Duration of Immune Response Following a 3rd Booster Dose of mRNA Vaccine Against COVID‐19 in 292 Patients With Hematological Malignancies in University Hospital Ostrava, Czech Republic |
| title_sort | one year duration of immune response following a 3rd booster dose of mrna vaccine against covid 19 in 292 patients with hematological malignancies in university hospital ostrava czech republic |
| topic | Cancer COVID‐19 Leukemia Lymphoma Myeloma Vaccination |
| url | https://doi.org/10.1002/cam4.70503 |
| work_keys_str_mv | AT ondrejsusol oneyeardurationofimmuneresponsefollowinga3rdboosterdoseofmrnavaccineagainstcovid19in292patientswithhematologicalmalignanciesinuniversityhospitalostravaczechrepublic AT barborasusolova oneyeardurationofimmuneresponsefollowinga3rdboosterdoseofmrnavaccineagainstcovid19in292patientswithhematologicalmalignanciesinuniversityhospitalostravaczechrepublic AT ondrejklempir oneyeardurationofimmuneresponsefollowinga3rdboosterdoseofmrnavaccineagainstcovid19in292patientswithhematologicalmalignanciesinuniversityhospitalostravaczechrepublic AT milannavratil oneyeardurationofimmuneresponsefollowinga3rdboosterdoseofmrnavaccineagainstcovid19in292patientswithhematologicalmalignanciesinuniversityhospitalostravaczechrepublic AT jaromirgumulec oneyeardurationofimmuneresponsefollowinga3rdboosterdoseofmrnavaccineagainstcovid19in292patientswithhematologicalmalignanciesinuniversityhospitalostravaczechrepublic AT zdenekkoristek oneyeardurationofimmuneresponsefollowinga3rdboosterdoseofmrnavaccineagainstcovid19in292patientswithhematologicalmalignanciesinuniversityhospitalostravaczechrepublic AT jurajduras oneyeardurationofimmuneresponsefollowinga3rdboosterdoseofmrnavaccineagainstcovid19in292patientswithhematologicalmalignanciesinuniversityhospitalostravaczechrepublic AT michalkascak oneyeardurationofimmuneresponsefollowinga3rdboosterdoseofmrnavaccineagainstcovid19in292patientswithhematologicalmalignanciesinuniversityhospitalostravaczechrepublic AT janamihalyova oneyeardurationofimmuneresponsefollowinga3rdboosterdoseofmrnavaccineagainstcovid19in292patientswithhematologicalmalignanciesinuniversityhospitalostravaczechrepublic AT lukasstejskal oneyeardurationofimmuneresponsefollowinga3rdboosterdoseofmrnavaccineagainstcovid19in292patientswithhematologicalmalignanciesinuniversityhospitalostravaczechrepublic AT tomasjelinek oneyeardurationofimmuneresponsefollowinga3rdboosterdoseofmrnavaccineagainstcovid19in292patientswithhematologicalmalignanciesinuniversityhospitalostravaczechrepublic AT petrarichterova oneyeardurationofimmuneresponsefollowinga3rdboosterdoseofmrnavaccineagainstcovid19in292patientswithhematologicalmalignanciesinuniversityhospitalostravaczechrepublic AT lenkaszeligova oneyeardurationofimmuneresponsefollowinga3rdboosterdoseofmrnavaccineagainstcovid19in292patientswithhematologicalmalignanciesinuniversityhospitalostravaczechrepublic AT hanaplonkova oneyeardurationofimmuneresponsefollowinga3rdboosterdoseofmrnavaccineagainstcovid19in292patientswithhematologicalmalignanciesinuniversityhospitalostravaczechrepublic AT janazuchnicka oneyeardurationofimmuneresponsefollowinga3rdboosterdoseofmrnavaccineagainstcovid19in292patientswithhematologicalmalignanciesinuniversityhospitalostravaczechrepublic AT barboradluhosova oneyeardurationofimmuneresponsefollowinga3rdboosterdoseofmrnavaccineagainstcovid19in292patientswithhematologicalmalignanciesinuniversityhospitalostravaczechrepublic AT ivodemel oneyeardurationofimmuneresponsefollowinga3rdboosterdoseofmrnavaccineagainstcovid19in292patientswithhematologicalmalignanciesinuniversityhospitalostravaczechrepublic AT davidbuffa oneyeardurationofimmuneresponsefollowinga3rdboosterdoseofmrnavaccineagainstcovid19in292patientswithhematologicalmalignanciesinuniversityhospitalostravaczechrepublic AT katarinahradska oneyeardurationofimmuneresponsefollowinga3rdboosterdoseofmrnavaccineagainstcovid19in292patientswithhematologicalmalignanciesinuniversityhospitalostravaczechrepublic AT terezapopkova oneyeardurationofimmuneresponsefollowinga3rdboosterdoseofmrnavaccineagainstcovid19in292patientswithhematologicalmalignanciesinuniversityhospitalostravaczechrepublic AT ludmilamuronova oneyeardurationofimmuneresponsefollowinga3rdboosterdoseofmrnavaccineagainstcovid19in292patientswithhematologicalmalignanciesinuniversityhospitalostravaczechrepublic AT martinlachnit oneyeardurationofimmuneresponsefollowinga3rdboosterdoseofmrnavaccineagainstcovid19in292patientswithhematologicalmalignanciesinuniversityhospitalostravaczechrepublic AT klaralancova oneyeardurationofimmuneresponsefollowinga3rdboosterdoseofmrnavaccineagainstcovid19in292patientswithhematologicalmalignanciesinuniversityhospitalostravaczechrepublic AT romanhajek oneyeardurationofimmuneresponsefollowinga3rdboosterdoseofmrnavaccineagainstcovid19in292patientswithhematologicalmalignanciesinuniversityhospitalostravaczechrepublic |